Pazopanib – dilemmas in kidney cancer treatment Review article
Article Sidebar
Main Article Content
Abstract
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in initial therapy where there are few drugs with similar properties. The choice of drug in first line is based on prognostic factors and clinical profiles of drug and patient. Important are also patient’s expectations connected with treatment. COMPARZ trail shows results of comparison between sunitinib and pazopanib which both are given in first line treatment of mRCC. Based on this the decision of choosing proper drug seems to be easier.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Motzer R.J., Hutson T.E., Tomczak P. et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27(22): 3584-90.
3. Sternberg C.N., Davies I.D., Mardiak J. et al.: Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma; Results of a Randomized Phase III Trial. J. Clin. Oncol. 2010; 28: 1061-68.
4. Motzer R.J., Thomas M.D., Hutson E. et al.: Pazopanib versus Sunitinib in Metastatic Renal Cell Carcinoma. N. Engl. J. Med. 2013; 369: 722-31.
5. Escudier B., Porta C., Bono P. et al.: Patient Preference Between Pazopanib and Sunitinib: Results of a Randomized Double-Blind, Placebo-Controlled, Crossover Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) (PISCES Study – NCT 01064310). ASCO 2012, Abstract 4502.
6. Rini B.I., Cohen D.P., Lu D.R. et al.: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. J. Natl. Cancer Inst. 2011; 103: 763-73.
7. Glavis V., Chow S., Thistlethwaite F.C. et al.: Clinical practice outcomes of patients treated with Pazopanib for metastatic Renal Cell Cancer (mRCC) – 6 year experience at referral centre in Manchester, UK. ESMO 2013, abstract.
8. Matrana M., Tarekeswara B., Shetty A. et al.: Outcomes of unselected patients with metastatic renal cell carcinoma (mRCC) treated with front line pazopanib therapy. ESMO 2013, abstract.